RxDoctor Payments Data

Julie Utendorf, MD

Family Medicine · Huntington, INNPI 1437158839

Payments from drug & device makers

$2,394in general payments, 2019–2025

Across 169 payments — averaging $14.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$565
  • Novo Nordisk$434
  • AstraZeneca$198
  • Lilly USA, LLC$180
  • Pfizer$141
  • Boehringer Ingelheim$118
  • plus $759 from 16 others

What the payments were for

  • Food & beverage$2,394100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,394 in reported general payments places this provider in the 75th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$59,237
Medicare patients
182
Services billed
990

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide110$160,090
TrulicityDulaglutide37$82,396
EliquisApixaban64$74,087
JardianceEmpagliflozin37$54,765
XareltoRivaroxaban25$39,048
InvokanaCanagliflozin18$34,956
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$26,507
FarxigaDapagliflozin Propanediol24$25,116
ProliaDenosumab11$19,392
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog18$19,083
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr21$16,340
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog14$15,737
CreonLipase/Protease/Amylase11$9,758
Xultophy 100-3.6Insulin Degludec/Liraglutide12$9,730
Breo ElliptaFluticasone/Vilanterol18$7,780

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Xultophy 100-3.6$434$169,821122 claims
Lilly USA, LLCTrulicity$180$82,39637 claims
PfizerEliquis$141$74,08764 claims
Boehringer IngelheimJardiance$118$54,76537 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$79$50,62757 claims
AstraZenecaFarxiga, Symbicort$198$30,76941 claims
AmgenProlia$79$19,39211 claims
AbbVieCreon, Synthroid$565$12,89357 claims
MerckDulera$45$6,62612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Huntington

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →